Lenalidomide maintenance therapy following autologous hematopoietic cell transplantation (HCT) results in a significantly longer time to disease progression and significantly improved overall survival among patients with multiple myeloma. The study analyzed outcomes of 460 patients <71 years of age undergoing autologous HCT who randomly received a placebo or lenalidomide therapy with a starting dose of 10 mg per day (range, 5 to 15). The median time to progression was 46 months in the lenalidomide group and 27 months in the placebo group (p<0.001). The rate of overall survival at 3 years was 88% among patients in the lenalidomide group and 80% in the placebo group (p=0.03). This trial was conducted by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN), Cancer and Leukemia Group B (CALGB), and CIBMTR (Center for International Blood and Marrow Transplant Research).
Lenalidomide after Autologous HCT for Multiple Myeloma Improves Survival